Lucas A. Horn, Ph.D.
Dr. Horn’s current research involves the development of innovative combination therapies for the treatment of cancer. His focus is on understanding mechanisms of tumor progression and therapy resistance, including the influence of tumor cell plasticity and the tumor extracellular matrix on immune cells in the tumor microenvironment.
1) tumor immunology, 2) cancer immunotherapy, 3) tumor progression, 4) tumor resistance to therapy, 5) cancer vaccines
The main goal of our research is to design and assess the efficacy of novel combination immunotherapies for the treatment of a range of human carcinomas. Our hypothesis-driven preclinical studies are used as rationale for the translation of these therapies into novel clinical trials. To achieve this goal, our research has focused on elucidating how mechanisms of tumor progression and therapy resistance, including tumor cell plasticity, tumor extracellular matrix, suppressive immune cells, and other factors influence the interplay of immune cells and tumor cells in the dynamic tumor microenvironment.
Selected Recent Publications
- Trends Cancer. 6(5): 432-441, 2020. [ Journal Article ]
Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity.J Immunother Cancer. 8(1): e000326, 2020. [ Journal Article ]
Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.Clin Cancer Res. 26(6): 1420-1431, 2020. [ Journal Article ]
- JCI Insight. 4(7): e126853, 2019. [ Journal Article ]
- Front Oncol. 10: 1548, 2020. [ Journal Article ]
Dr. Lucas Horn received his Ph.D. in Biological Sciences from the University of Maryland Baltimore County (UMBC) in 2017. He subsequently joined the Laboratory of Tumor Immunology and Biology (LTIB), Center for Cancer Research, NCI, NIH, as a Postdoctoral Fellow, and was appointed as a Staff Scientist in 2020. Dr. Horn’s current research is focused on the development of novel immunotherapeutic approaches aimed at promoting immune cell activation while altering tumor cell plasticity and the suppressive tumor microenvironment.